| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,651,000 |
| Market
Cap: |
570.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.84 - $28.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quanterix is a life sciences company that has developed digital immunoassay platforms. Co.'s platforms are based on its proprietary digital Simoa detection technology. Co. provides the following three Simoa instruments: HD-X, which is based on Co.'s bead-based technology, and assays run on the HD-X are fully automated; SR-X, which utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a range of applications; and SP-X, which is based on Co.'s planar array technology, which allows for multiplexing capabilities for oncology and immunology applications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
20,200 |
639,331 |
| Total Buy Value |
$0 |
$0 |
$501,978 |
$6,053,841 |
| Total People Bought |
0 |
0 |
1 |
7 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
2,500 |
5,000 |
5,000 |
10,265 |
| Total Sell Value |
$60,025 |
$119,770 |
$119,770 |
$214,084 |
| Total People Sold |
1 |
1 |
1 |
5 |
| Total Sell Transactions |
2 |
4 |
4 |
15 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dekkers Marijn E |
|
– • – |
2021-06-04 |
4 |
OE |
$8.16 |
$89,164 |
D/D |
5,119 |
14,199 |
|
- |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-06-02 |
4 |
AS |
$48.96 |
$246,085 |
D/D |
(5,000) |
955,925 |
|
-14% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-06-01 |
4 |
AS |
$48.32 |
$186,218 |
D/D |
(3,854) |
960,925 |
|
-3% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2021-06-01 |
4 |
S |
$48.32 |
$7,393 |
D/D |
(153) |
24,136 |
|
3% |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2021-06-01 |
4 |
S |
$48.32 |
$10,920 |
D/D |
(226) |
34,389 |
|
3% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-06-01 |
4 |
S |
$48.32 |
$11,741 |
D/D |
(243) |
32,733 |
|
3% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2021-05-28 |
4 |
AS |
$51.00 |
$85,017 |
D/D |
(1,667) |
34,951 |
|
-9% |
|
| Crandell Keith |
Director |
– • – |
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
11,236 |
75,634 |
|
- |
|
| Crandell Keith |
Director |
– • – |
2021-05-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(350,000) |
475,070 |
|
- |
|
| Crandell Keith |
Director |
– • – |
2021-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
11,237 |
64,398 |
|
- |
|
| Crandell Keith |
Director |
– • – |
2021-05-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(350,000) |
611,330 |
|
- |
|
| Crandell Keith |
Director |
– • – |
2021-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,237 |
53,161 |
|
- |
|
| Crandell Keith |
Director |
– • – |
2021-05-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(350,000) |
747,590 |
|
- |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-05-13 |
4 |
AS |
$45.46 |
$231,491 |
D/D |
(5,000) |
964,779 |
|
13% |
|
| Stetson Shawn |
Interim CFO and Treasurer |
• – – |
2021-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,423 |
4,712 |
|
- |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2021-05-03 |
4 |
S |
$57.25 |
$12,557 |
D/D |
(217) |
34,615 |
|
15% |
|
| Chaubal Amol |
Chief Financial Officer |
• – – |
2021-05-03 |
4 |
S |
$57.25 |
$10,299 |
D/D |
(178) |
30,222 |
|
15% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-05-03 |
4 |
S |
$57.25 |
$13,538 |
D/D |
(234) |
32,976 |
|
15% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-05-03 |
4 |
AS |
$57.25 |
$336,952 |
D/D |
(5,789) |
969,779 |
|
-15% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2021-05-03 |
4 |
S |
$57.25 |
$8,505 |
D/D |
(147) |
24,289 |
|
15% |
|
| Olson Laurie J |
|
– • – |
2021-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,540 |
4,540 |
|
- |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-04-20 |
4 |
AS |
$57.87 |
$291,142 |
D/D |
(5,000) |
975,568 |
|
-13% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2021-04-15 |
4 |
AS |
$62.14 |
$103,587 |
D/D |
(1,667) |
36,618 |
|
-19% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-04-08 |
4 |
AS |
$65.01 |
$327,703 |
D/D |
(5,000) |
980,568 |
|
-30% |
|
| Crandell Keith |
Director |
– • – |
2021-04-01 |
4/A |
A |
$61.45 |
$12,966 |
D/D |
211 |
41,924 |
|
- |
|
278 Records found
|
|
Page 6 of 12 |
|
|
0.03 (0.19%) 
